The role of prevention

Handbook of Clinical Neurology

Volumn 97, Issue C, 2010, Pages 195-205

  Tepper, Stewart J ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE;

HEADACHE; HUMAN; MIGRAINE;

AMITRIPTYLINE; HEADACHE; HUMANS; MIGRAINE DISORDERS;

EID: 77956272008     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(10)97015-2     Document Type: Book

References (67)

1. Ablad B., Dahlof C. Migraine and beta-blockade: modulation of sympathetic neurotransmission. Cephalalgia 1986, 6:7-13.
2. Ambrosini A., Maertens de Noordhout A., Schoenen J., et al. Neuromuscular transmission in migraine: a single-fiber EMG study in clinical subgroups. Neurology 2001, 56:1038-1043.
3. Ayata C., Jin H., Kudo C., et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006, 59:652-661.
4. Bigal M.E., Bordini C.A., Tepper S.J., et al. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia 2002, 22:345-353.
5. Bolay H., Reuter U., Dunn A.K., et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002, 8:136-142.
6. Brandes J.L., Saper J.R., Diamond M., et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004, 291:965-973.
7. Bulut S., Berilgen M.S., Baran A., et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004, 107:44-48.
8. Burstein R., Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004, 55:27-36.
9. Burstein R., Collins B., Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004, 55:19-26.
10. Cohen G.K. Migraine prophylactic drugs work via ion channels. Med Hypotheses 2005, 65:114-122.
11. Cutrer F.M., Moskowitz M.A. Wolff award 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache 1996, 36:579-585.
12. Cutrer F.M., Limmroth V., Moskowitz M.A. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia 1997, 17:93-100.
13. Diamond S., Bigal M.E., Silberstein S., et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention Study. Headache 2007, 47:355-363.
14. Diener H.C., Tfelt-Hansen P., Dahlof C., et al. Topiramate in migraine prophylaxis - results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004, 251:943-950.
15. Grossman M., Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 2000, 38:430-435.
16. Gursoy-Ozdemir Y., Chu J., Matsuoka N., et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004, 113:1447-1455.
17. Heninger G.R., Charney D.S. Mechanism of action of antidepressant treatments: implications for the etiology and treatment of depressive disorders. Psychopharmacology: The Third Generation of Progress 1987, 535-544. Raven Press, New York. H.Y. Meltzer (Ed.).
18. Joffe H., Cohen L.S., Suppes T., et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006, 59:1078-1086.
19. Katsarava Z., Schneeweiss S., Kurth T., et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004, 62:788-790.
20. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997, 17:103-108.
21. Lampl C., Katsarava Z., Diener H.C., et al. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 2005, 76:1730-1732.
22. Lipton R.B., Silberstein S.D., Saper J.R., et al. Why headache treatment fails. Neurology 2003, 60:1064-1070.
23. Lipton R.B., Gobel H., Einhäupl K.M., et al. Petasites hybridus root (butterbur) is an effective treatment for migraine. Neurology 2004, 63:2240-2244.
24. Lipton R.B., Bigal M.E., Diamond M., et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007, 68:343-349.
25. Mathew N.T., Rapoport A., Saper J., et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001, 41:119-128.
26. 2+ ratio. Headache 1993, 33:135-138.
27. Miljanich G.P., Ramachandran J. Antagonists of neuronal calcium channels: structure, function, and therapeutic implications. Annu Rev Pharmacol Toxicol 1995, 35:707-734.
28. Moskowitz M.A. Basic mechanisms in vascular headache. Neurol Clin 1990, 8:801-815.
29. Moskowitz M.A. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992, 13:307-311.
30. Moskowitz M.A. Interpreting vessel diameter changes in vascular headaches. Cephalalgia 1992, 12:5-7.
31. Moskowitz M.A. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992, 13:307-311.
32. Muller S.E. Ergot alkaloids in migraine: is the effect via 5-HT receptors. 5-Hydroxytryptamine Mechanisms in Primary Headaches 1992, 297-304. Raven Press, New York. J. Olesen, P.R. Saxena (Eds.).
33. 2+ channel gene CACNLA4. Cell Tissue Res 1986, 87:543-552.
34. Ozyalcin S.N., Talu G.K., Kiziltan E., et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005, 45:144-152.
35. Peikert A., Wilimzig C., Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996, 16:257-263.
36. Peroutka S.J. Developments in 5-hydroxytriptamine receptor pharmacology. Headache. Neurologic Clinics 1990, Vol. 8:829-839. WB Saunders, Philadelphia. N.T. Mathew (Ed.).
37. Petroff O.A., Rothman D.L., Behar K.L., et al. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996, 39:95-99.
38. Pietrobon D., Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 2003, 4:386-398.
39. Ramadan N.M. Prophylactic migraine therapy: mechanisms and evidence. Curr Pain Headache Rep 2004, 8:91-95.
40. Ramadan N.M., Halvorson H., Vande-Linde A., et al. Low brain magnesium in migraine. Headache 1989, 29:590-593.
41. Ramadan N.M., Silberstein S.D., Freitag F.G., et al. Multispecialty consensus on diagnosis and treatment of headache: pharmacological management for prevention of migraine. Neurology serial online 2000, available online at:. http://www.aan.com/professionals/practice/pdfs/gl0090.pdf.
42. Raskin N.H., Hosobuchi Y., Lamb S. Headache may arise from perturbation of brain. Headache 1987, 27:416-420.
43. Read S.J., Hirst W.D., Upton N., et al. Cortical spreading depression produces increased cGMP levels in cortex and brain stem that is inhibited by tonabersat (SB-220453) but not sumatriptan. Brain Res 2001, 891:69-77.
44. Sandor P.S., Mascia A., Seidel L., et al. Subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements. Ann Neurol 2001, 49:668-672.
45. Sandor P.S., DiClemente L., Coppola G., et al. A randomized controlled trial of coenzyme Q10 in migraine prophylaxis. Neurology 2005, 64:713-715.
46. Scher A.I., Stewart W.F., Ricci J.A., et al. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003, 106:81-89.
47. Schoenen J., Jacquy J., Lanaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology 1998, 50:466-470.
48. Schrader H., Stovner L.J., Helde G., et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001, 322:19-22.
49. Shank R.P., Gardocki J.F., Streeter A.J., et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000, 41(Suppl. I):S3-S9.
50. Sheftell F., Rapoport A., Weeks R., et al. Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers. Headache 2000, 40:158-163.
51. Silberstein S.D. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55:754-762.
52. Silberstein S.D., Goadsby P.J. Migraine: preventive treatment. Cephalalgia 2002, 22:491-512.
53. Silberstein S.D., Lipton R.B., Goadsby P.J. Headache in Clinical Practice 2000, 91-92. Martin Dunitz, Oxford. 2nd edn.
54. Silberstein S.D., Neto W., Schmitt J., et al. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004, 61:490-495.
55. Silberstein S., Loder E., Diamond S., et al. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study. Cephalalgia 2007, 27:220-234.
56. Steiner T.J., Findley L.J., Yuen A.W. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997, 17:109-112.
57. Storer R.J., Goadsby P.J. Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia 2004, 24:1049-1056.
58. Taiwo Y.O., Levine J.D. Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia. Neuroscience 1991, 44:131-135.
59. Taylor C.P., Gee N.S., Su T.Z., et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998, 29:233-248.
60. Theis M., Sohl G., Eiberger J., et al. Emerging complexities in identity and function of glial connexins. Trends Neurosci 2005, 28:188-195.
61. Tronvik E., Stovner L.J., Helde G., et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003, 289:65-69.
62. Wauquier A., Ashton D., Marranes R. The effects of flunarizine in experimental models related to the pathogenesis of migraine. Cephalalgia 1985, 5:119-120.
63. Weiller C., May A., Limmroth V., et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995, 1:658-660.
64. Welch K.M.A., Chabi E., Bartosh K., et al. Cerebrospinal fluid gamma aminobutyric acid levels in migraine. BMJ 1975, 3:516-517.
65. Woods R.P., Iacoboni M., Mazziotta J.C. Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994, 331:1689-1692.
66. Zeise M.L., Kasparow S., Zieglgansberger W. Valproate suppresses N-methyl-d-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res 1991, 544:345-348.
67. Ziad el K., Rahi A.C., Hamdan S.A., et al. Age, dose, and environmental temperature are risk factors for topiramate-related hyperthermia. Neurology 2005, 65:1139-1140.